Free Trial
NASDAQ:CMMB

Chemomab Therapeutics Q1 2026 Earnings Results & Report

Chemomab Therapeutics logo
$1.53 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.54 +0.01 (+0.98%)
As of 11/13/2026 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Chemomab Therapeutics missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.22 versus the -$0.04 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Chemomab Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Chemomab Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Chemomab Therapeutics Q1 2026 Earnings FAQ

Chemomab Therapeutics (NASDAQ:CMMB) reported earnings of -$0.22 per share for Q1 2026, missing the consensus estimate of -$0.04. The report was announced on Thursday, May 14, 2026.

Chemomab Therapeutics Earnings Headlines

Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
See More Chemomab Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring.

The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis.

Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics. Its leadership has included co-founder Yuval Cohen as chief executive officer.

View Chemomab Therapeutics Profile